Loading the security page…
Nasdaq · INDV
Prices delayed by 15 minutes
This security is no longer traded.
A security analysis is not yet prepared for this market.
The series is stated in the current share scale after splits; dividends are not included in the price
Indivior Pharmaceuticals, Inc. (INDV) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-06-30, revenue was 1.3bn $, net income was 356.0m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Indivior Pharmaceuticals, Inc. (INDV) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Indivior Pharmaceuticals, Inc. (INDV) on October 30, 2026 is 35.53 $, +0.81 % on the day. Over 52 weeks the stock traded between 23.67 $ and 42.81 $; the price now sits 62 % of the way up that range. Over the past year the price changed by +39.20 %. The P/E ratio is 12.48, which is below the sector median (24.61). Market capitalization is 4.44 billion $, rank 44 among 379 stocks of the same industry with a known capitalization.
Indivior Pharmaceuticals, Inc. trades on Nasdaq under the ticker INDV. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks INDV has traded between 23.67 $ and 42.81 $. As of 30 October 2026 the price stood 54.81 % of the way from the 52-week low to the high.
Over one year INDV shares rose 39.20 %; over six months they rose 5.04 %. Volatility over 90 days is 28.90 %. Dividends are not included: this is price change only, as of 30 October 2026.
INDV trades at a price-to-earnings ratio of 12.5, below the sector median of 24.6. Price to sales is 3.3, below the sector median of 3.6. Calculated from reports for the period ending 30 June 2026.
Indivior Pharmaceuticals, Inc. reported revenue of 1.3B $ and net income of 356M $ over the last four quarters. Net margin is 26.75 %. Revenue changed by +13.47 % year over year. Earnings per share are 2.79 $. Market capitalisation is 4.4B $.